Imatinib

Generic Name: Imatinib

Brand Names: Gleevec, Glivec, Imatinib Teva, Imatinib Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₁N_₇O

CAS Number: 152459-95-5

Unique Ingredient Identifier: BKJ8M8G5HI

Background: Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient.

Indication: Imatinib is indicated for the treatment of adult and pediatric chronic myeloid leukemia with Philadelphia chromosome mutation (Ph+) in blast crisis, accelerated phase, or chronic phase after IFN-alpha therapy failure.Additionally, imatinib is also indicated to treat adult and pediatric Ph+ acute lymphoblastic leukemia, adult myelodysplastic/myeloproliferative diseases, adult aggressive systemic mastocytosis, adult hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), adult dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).

Associated Conditions: Accelerated Phase Chronic Myelogenous Leukemia (CML), Aggressive Systemic Mastocytosis, Chordomas, Chronic Eosinophilic Leukemia, FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia, FIP1L1-PDGFRα fusion kinase status unknown Hypereosinophilic syndrome, Gastrointestinal Stromal Tumor (GIST), Hypereosinophilic Syndrome (HES), Metastatic Gastrointestinal Stromal Tumor (GIST), Metastatic Melanoma, Myelodysplastic Syndrome, Myeloproliferative Disorders (MPD), Refractory Acute Lymphoblastic Leukemia (ALL), Blast phase Chronic myeloid leukemia, CKit mutational status unknown Aggressive systemic mastocytosis, Metastatic Dermatofibrosarcoma protuberans, Newly diagnosed Acute Lymphoblastic Leukaemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Recurrent Dermatofibrosarcoma protuberans, Refractory, chronic phase Chronic myeloid leukemia, Unresectable Gastrointestinal stromal tumor

Clinical Trials

Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL

Phase 4

Terminated

Conditions: Acute Leukemia

Interventions: Drug: Imatinib
Drug: Flumatinib

First Posted Date: 2021-10-08

Last Posted Date: 2025-05-01

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 39

Registration Number: NCT05071482

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China

Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)

Phase 2

Recruiting

Conditions: Advanced Gastrointestinal Stromal Tumor (GIST)
Metastatic Gastrointestinal Stromal Tumor (GIST)
C-KIT Mutation

Interventions: Drug: Imatinib tablets

First Posted Date: 2021-08-18

Last Posted Date: 2023-09-01

Lead Sponsor: Centre Leon Berard

Target Recruit Count: 50

Registration Number: NCT05009927

Locations: 🇫🇷
Institut de Cancérologie Lucien NEUWIRTH, Saint-Paul-en-Jarez, France
🇫🇷
CHU de Reims, Reims, France
🇫🇷
Institut Claudius Regaud, Toulouse, France

and more 10 locations

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Phase 3

Active, not recruiting

Conditions: Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

Interventions: Drug: Asciminib
Drug: Imatinib
Drug: Nilotinib
Drug: Bosutinib
Drug: Dasatinib

First Posted Date: 2021-07-21

Last Posted Date: 2025-04-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 406

Registration Number: NCT04971226

Locations: 🇺🇸
Rocky Mountain Cancer Centers, Longmont, Colorado, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Florida Cancer Specialists Pan, Tallahassee, Florida, United States

and more 10 locations

A Randomized Study to Investigate the Effect of Intravenous Imatinib on the Amount of Oxygen in the Lungs and Blood of Adults With COVID-19 Needing Mechanical Ventilation and Supportive Care.

Phase 2

Withdrawn

Conditions: COVID-19 Acute Respiratory Distress Syndrome
Covid19
ARDS
Acute Respiratory Distress Syndrome
Pulmonary Oedema

Interventions: Drug: Imatinib Mesylate
Drug: Placebo

First Posted Date: 2021-07-07

Last Posted Date: 2022-07-28

Lead Sponsor: Exvastat Ltd.

Registration Number: NCT04953052

Locations: 🇮🇳
St George's Hospital, P D Mello Road, Fort Road, CST Terminal,, Mumbai, Maharashtra, India
🇮🇳
Indira Gandhi Government Medical College and Hospital, Nagpur, India
🇮🇳
NRS Medical College and Hospital, Kolkata, West Bengal, India

and more 5 locations

Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors

Phase 2

Recruiting

Conditions: Gastrointestinal Stromal Tumor
Progression-free Survival
Neoadjuvant

Interventions: Drug: Imatinib

First Posted Date: 2021-06-22

Last Posted Date: 2021-10-12

Lead Sponsor: First Affiliated Hospital of Zhejiang University

Target Recruit Count: 122

Registration Number: NCT04933669

Locations: 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Asciminib Roll-over Study

Phase 4

Recruiting

Conditions: Chronic Myelogenous Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Interventions: Drug: Bosutinib
Drug: Imatinib
Drug: Asciminib single agent
Drug: Nilotinib
Drug: Dasatinib

First Posted Date: 2021-05-07

Last Posted Date: 2025-05-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 347

Registration Number: NCT04877522

Locations: 🇺🇸
Michigan Med University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
Memorial Sloan Kettering, New York, New York, United States
🇺🇸
Oregon Health Sciences University, Portland, Oregon, United States

and more 2 locations

Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Phase 2

Recruiting

Conditions: Chronic Phase Chronic Myelogenous Leukemia

Interventions: Drug: Asciminib 40 MG
Drug: Asciminib 80 MG daily
Drug: Asciminib 40 MG Twice Daily
Drug: Imatinib
Drug: Dasatinib
Drug: Nilotinib

First Posted Date: 2021-04-08

Last Posted Date: 2025-04-23

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 51

Registration Number: NCT04838041

Locations: 🇺🇸
The Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States

and more 1 locations

Intravenous Imatinib in Mechanically Ventilated COVID-19 Patients

Phase 2

Terminated

Conditions: Endothelial Dysfunction
Acute Respiratory Distress Syndrome
Covid19
ARDS
Pulmonary Edema

Interventions: Drug: Placebo
Drug: Imatinib Mesylate intravenous solution

First Posted Date: 2021-03-11

Last Posted Date: 2023-01-23

Lead Sponsor: Dr. Jurjan Aman

Target Recruit Count: 67

Registration Number: NCT04794088

Locations: 🇳🇱
Amsterdam Universitair Medische Centra, location VUmc, Amsterdam, Noord-Holland, Netherlands
🇳🇱
Amsterdam Universitair Medische Centra, location AMC, Amsterdam, Noord-Holland, Netherlands

Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

Phase 3

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
ALL, Adult
Philadelphia-Positive ALL

Interventions: Drug: Ponatinib + Blinatumomab
Drug: Chemotherapy + Imatinib

First Posted Date: 2021-01-25

Last Posted Date: 2025-01-23

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 236

Registration Number: NCT04722848

Locations: 🇮🇹
Ente Ecclesiastico Casa Sollievo Della Sofferenza - San Giovanni Rotondo - Ematologia, San Giovanni Rotondo, Italy
🇮🇹
Aou Senese - Uoc Ematologia E Trapianti, Siena, Italy
🇮🇹
Asui Di Udine - Presidio Ospedaliero "Santa Maria Della Misericordia" - Clinica Ematologica, Udine, Italy

and more 12 locations

Study in Adult Ph-positive ALL

Phase 2

Not yet recruiting

Conditions: Acute Lymphoblastic Leukemia, Adult

Interventions: Drug: Imatinib
Drug: Ponatinib
Drug: Blinatumomab

First Posted Date: 2020-12-30

Last Posted Date: 2020-12-30

Lead Sponsor: Cardiff University

Target Recruit Count: 180

Registration Number: NCT04688983

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy